Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

E-Cigarettes: No Definitive Evidence on Their Potential Cardiovascular Effect, but Some Suggest Caution

E-cigarettes may bring about cardiac risk according to a new literature review soon to be published in J Am Coll Cardiol. The evidence on potential harm is not definitive, but some experts suggest caution in their use until there is more solid evidence.

E-cigarettes have been advertised as a healthy alternative to traditional cigarettes and an aid for tobacco cessation, but recent evidence suggests that they might cause adverse cardiovascular events.

 

Such events involve endothelial function, vascular stiffness, vasoconstriction, heart rate, blood pressure, inflammation, oxidative stress, and platelet function (all of which have already been observed with e-cigarettes). While e-cigarettes are widely believed to be safe (in terms of both cardiovascular risk and cancer), the truth is that they have not been studied enough. In fact, we could say that there is not enough solid evidence confirming that e-cigarettes even help people to quit smoking conventional cigarettes.


Read also: Several Features Define a Hostile Neck in AAA patients, but Only One Makes the Difference.


These devices can only be considered another tool to help people quit smoking.

 

If they do help smokers to quit conventional cigarettes, their potential for public health benefit is huge. However, this potential benefit must be balanced against their long-term health risks, which are still unknown.

 

Researchers reviewed 14 studies (all of them carried out in developed countries) that suggest possible cardiovascular harm and note that e-cigarettes are available in most countries around the world without any regulation.


Read also: Early Strut Coverage and Its Implications for Dual Antiplatelet Therapy.


We have a responsibility to inform our patients that e-cigarettes contain chemicals whose long-term effects are currently unknown. For smokers, this may be the lesser evil, but we should emphasize the fact that we still lack enough evidence.

 

Original title: 2018 ACC Expert Consensus Decision Pathway on Tobacco Cessation Treatment.

Reference: Barua RS et al. J Am Coll Cardiol. 2018; Epub ahead of print.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

EuroPCR 2026 | P2Y12 Inhibitor Monotherapy After Complex PCI in ACS: Results From the NEO-MINDSET COMPLEX Subanalysis

This is a summary of the NEO-MINDSET COMPLEX subanalysis, presented by Dr. Guy Prado at EuroPCR 2026, which evaluated P2Y12 inhibitor monotherapy versus dual...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

EuroPCR 2026 | Could clopidogrel replace aspirin as monotherapy after PCI?

This presentation, delivered during EuroPCR 2026, analyzed the clinical outcomes of clopidogrel monotherapy versus aspirin in patients who remained event-free for 12 months after...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...